News

Why Is Kairos Pharma Stock Surging On Tuesday?
Kairos Pharma reported strong safety results from a Phase 2 trial of ENV-105 in mCRPC, with no serious toxicities seen in the ...
Investornewsbreaks Kairos Pharma Ltd. (NYSE American: KAPA) To Present At H.C. Wainwright Global Investment Conference
Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company advancing cancer therapeutics, will participate in the H.C. Wainwright 27th ...
The Bakersfield Californian8h
Kairos Pharma Announces Participation and Presentation in the H.C. Wainwright 27th Annual Global Investment Conference September 8-10, 2025
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces participation and presentation at the H.C. Wainwright ...
InvestorsHub on MSN1d
Kairos Pharma Shares Surge on Promising Safety Data for Prostate Cancer Treatment
Kairos Pharma Ltd (NYSE:KAPA) saw its stock jump 165% following the announcement of encouraging safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients battling metastatic ...
CURE5h
Carotuximab Combo Proves Safe for Advanced Prostate Cancer
Carotuximab plus Erleada proved safe in the first 10 patients with metastatic castration-resistant prostate cancer dosed on ...
Kairos Pharma Announces Positive Safety Results from Phase 2 Trial of ENV-105 in Advanced Prostate Cancer
Kairos Pharma, Ltd. (NYSE American:KAPA), a clinical-stage biopharmaceutical company focused on innovative cancer therapeutics, today announces positive safety results from its ongoing Phase 2 ...
Kairos Pharma Shares Surge on Prostate Cancer Study Results
Kairos Pharma shares were higher as the company reported positive safety results from a clinical trial of ENV-105, or carotuximab, in patients with metastatic castration-resistant prostate cancer.
Investing.com South Africa1d
Kairos Pharma stock soars after positive safety data for cancer drug
Investing.com -- Kairos Pharma Ltd (NYSE: KAPA) stock surged 165% after the clinical-stage biopharmaceutical company reported positive safety results from its ongoing Phase 2 clinical trial of ENV-105 ...
Biomednewsbreaks - Kairos Pharma Ltd. (NYSE American: KAPA) Reports Positive Safety Results In Phase 2 Study Of Prostate Cancer Drug ENV-105
Kairos Pharma (NYSE American: KAPA) , a clinical-stage biopharma company developing cancer therapies, announced favorable interim safety results from ...
Nasdaq7mon
Kairos Pharma Approved to Dual List on Upstream | Nasdaq
LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a MERJ Exchange market and global securities trading app ...
Finanznachrichten1mon
D.Boral Capital: Kairos Pharma, Ltd. Announces Participation in the D ...
Los Angeles, California--(Newsfile Corp. - May 6, 2025) - Kairos Pharma, Ltd. (NYSE American: KAPA) today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place ...
Yahoo Finance7mon
Kairos Pharma Approved to Dual List on Upstream - Yahoo Finance
Trading to begin November 26, 2024 under ‘KAPA’LOS ANGELES, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Kairos Pharma, Ltd. (KAPA) today announced its approval to dual list its shares on Upstream, a ...